Reduced Rejection Risk
Unlike traditional donor corneas, rHCT3-I is a bioengineered implant that closely mimics the natural corneal stroma, significantly reducing the risk of tissue rejection.
Bioengineered Precision
The rHCT3-I implant is crafted from recombinant collagen, replicating the natural collagen-rich structure of the cornea. This precision design ensures better integration and function, providing a more effective solution for corneal repair.
Enhanced Safety
The advanced design of rHCT3-I offers a safer option for patients by avoiding complications associated with donor tissue, such as transmission of diseases and compatibility issues.
Improved Accessibility
As a bioengineered solution, rHCT3-I can be produced on-demand, increasing accessibility for patients who need corneal replacements and potentially alleviating the global shortage of donor corneas.
Corneal blindness is the 4th leading cause of vision loss around the world.
Are born or develop infections at a young age, which cause corneal blindness
Corneal blindness is a significant global issue, with only one cornea available for every 70 needed. Even when donor corneas are available, there is always a risk of tissue rejection, necessitating at least a year of immunosuppressive medication post-transplant. To address this, we are developing rHCT3-I, a recombinant collagen film/implant designed to replace damaged or lost corneal stroma. This bioengineered cornea mimics the natural cornea’s collagen-rich structure without containing impurities, human cells, or cellular material, significantly reducing the risk of rejection compared to donated corneas. This offers a promising solution for those affected by corneal blindness, providing a safer and more accessible alternative to traditional corneal transplants.